Keywords: zidovudine, arm, actg, halted, interim, results, trial
Zidovudine Arm Of ACTG 152 Halted
Article | 20 February 1995
Interim results of the ACTG 152 trial comparing Wellcome's Retrovir (zidovudine), Bristol-Myers Squibb's Videx (didanosine) and a combination of the two ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
